Author

K. C. Refvik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Organism:mouse· 1

Frequent Co-Authors

A. J. Slezak· 3 shared A. Solanki· 3 shared A. T. Alpar· 3 shared J. A. Hubbell· 3 shared R. P. Wallace· 3 shared A. L. Lauterbach· 2 shared L. A. Hesser· 2 shared M. Nguyen· 2 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

A. J. Slezak

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Engineered Flt3L Drives Tolerogenic State to Attenuate Anti-drug Antibody Responses

A. T. Alpar, R. P. Wallace, K. C. Refvik, S. Gomes, A. Solanki, L. T. Gray, A. J. Slezak, A. L. Lauterbach, L. A. Hesser, S. Cao, J. E. G. Medellin, L. G. Robinson, J. A. Hubbell

The paper describes a method using engineered Flt3L to induce a tolerogenic immune state, reducing anti-drug antibodies to a fungal enzyme.

bioRxiv · Mar 21, 2024 · PreprintBioengineering

Suppression of autoimmune arthritis and neuroinflammation via an amino acid-conjugatedbutyrate prodrug with enhanced oral bioavailability

S. Cao, E. Budina, M. M. Raczy, A. Solanki, M. Nguyen, T. N. Beckman, J. W. Reda, K. Hultgren, P. Ang, A. J. Slezak, L. A. Hesser, A. T. Alpar, K. C. Refvik, L. S. Shores, I. Pillai, , J. A. Hubbell

This study develops a butyrate prodrug, SerBut, which improves oral bioavailability and reduces autoimmune arthritis and neuroinflammation in mouse models.

bioRxiv · Apr 28, 2023 · PreprintBioengineering

Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics

R. P. Wallace, K. C. Refvik, J. T. Antane, K. Brünggel, A. C. Tremain, M. R. Raczy, A. T. Alpar, M. Nguyen, A. Solanki, A. J. Slezak, E. A. Watkins, A. L. Lauterbach, D. S. Wilson, J. A. Hubbell

This study shows that conjugating immunogenic biologics to a synthetic mannose polymer reduces anti-drug antibody responses by impairing T cell and B cell responses.

bioRxiv · Apr 7, 2023Bioengineering